Ephrin Receptor



Ephrin receptors (Ephs) are a group of receptors that are activated in response to binding ephrin. Ephs form the largest known subfamily of receptor tyrosine kinases (RTKs). Both Ephs and their corresponding ephrin ligands are membrane-bound proteins that require direct cell-cell interactions for Eph receptor activation. Eph/ephrin signaling has been implicated in the regulation of a host of processes critical to embryonic development including axon guidance, formation of tissue boundaries, cell migration, and segmentation. Additionally, Eph/epherin signaling has recently been identified to play a critical role in the maintenance of several processes during adulthood including long-term potentiation, angiogenesis, and stem cell differentiation and cancer. The ability of Ephs and ephrins to mediate a variety of cell-cell interactions places the Eph/ephrin system in an ideal position to regulate a variety of different biological processes during embryonic development.

Ephrin Receptor Inhibitors & Modulators

ALW-II-41-27

(Eph receptor tyrosine kinase inhibitor) **Cat. No.**: HY-18007

Bioactivity: ALW-II-41-27 is a **Eph** family tyrosine kinase inhibitor with an $\mathbf{IC_{50}}$ of 11 nM for Eph2.

Purity: 99.38%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg



JI-101

Cat. No.: HY-16265

Bioactivity: JI-101 is an orally available multi-kinase inhibitor of **VEGFR2 PDGFRβ** and **EphB4** with potent anti-cancer activity.

Purity: 99.95%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg



NVP-BHG712 isomer

(NVPiso) **Cat. No.**: HY-13258

Bioactivity: NVP-BHG712 isomer, a regioisomer of NVP-BHG712, shows conserved non-bonded binding to EPHA2 and EPHB4 [1].

Purity: 99.51%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg



Tesevatinib

(XL-647; EXEL-7647; KD-019) **Cat. No.**: HY-13314

Bioactivity: Tesevatinib (XL-647) is an orally available, multi-target tyrosine kinase inhibitor; inhibits **EGFR**, **ErbB2**, **KDR**, **Flt4** and **EphB4** kinase with $\mathbf{IC_{50}}$s of 0.3, 16, 1.5, 8.7, and 1.4 nM.

Purity: 99.21%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg



Tel: 609-228-6898 Fax: 609-228-5909 Email: sales@MedChemExpress.com